Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Brian Jensen
Univ of North Carolina Chapel Hill, Department: Radiation Diagnostic/oncology
Should you be removed from our database? Contact us at [email protected]. Read more below.
AdrenaRx, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The SFIs of the investigator are related to the funded research since the technology being used in the project has been licensed to the company with which the investigator has multiple relationships.
The Institution has determined that since the technology could be further validated as a result of the research, these financial interests could conflict with project.
Metabolic mechanisms of cardioprotection through alpha-1A adrenergic receptor activation
PROJECT NARRATIVE Adrenaline and noradrenaline activate both alpha-1 and beta- adrenergic receptors (ARs) in the heart. Chronic stimulation of beta-ARs by elevated levels of these hormones causes heart failure. In contrast, activation of alpha-1-ARs protects the heart, though the mechanisms that account for this benefit are currently unknown. In this proposal, we will expand upon our recent findings suggesting that alpha-1A-ARs protect the heart by providing more energy for heart muscle cells through more efficient metabolism of glucose. We will use a safe oral drug that selectively stimulates alpha-1A-ARs in these experiments, to lay the groundwork for our long- term goal of developing a novel therapy for heart failure.
Filed on February 21, 2019.
Tell us what you know about Brian Jensen's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Brian Jensen filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Brian Jensen | Univ of North Carolina Chapel Hill | Conflict of Interest | AdrenaRx, Inc. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.